Please ensure Javascript is enabled for purposes of website accessibility

Approvals and Orders for Co-Diagnostics' COVID-19 Test Kits Are on the Rise

By Cory Renauer – May 4, 2020 at 2:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Demand for its coronavirus diagnostic kits could spike in the months ahead.

The Mexican Department of Epidemiology has approved for sale a COVID-19 diagnostic test manufactured by Co-Diagnostics (CODX 1.60%). In addition, CoSara, a joint venture that the molecular diagnostics company formed in India, has also been cleared to sell test kits in the world's second-most populous country.  

Spreading demand 

Demand for Co-Diagnostics products has soared since the FDA granted it an emergency use authorization (EUA) to sell the Logix Smart COVID-19 test on April 3. The Centers for Medicare and Medicaid Services (CMS), which regulates all U.S. laboratory testing performed on humans, has also approved the sale of the test to roughly 260,000 clinical laboratories across the country. 

Automated laboratory equipment.

Image source: Getty Images.

On Monday, Co-Diagnostics said orders for the Logix Smart COVID-19 test are still strong across the U.S., and that demand is spreading. Unfortunately, the company did not provide any recent sales figures to quantify just how strong that domestic demand has been.

In addition, Co-Diagnostics' could soon begin to record ballooning sales of test kits abroad. Earlier this month, the company released some amazing performance data that should boost demand in Mexico, India, and dozens of other countries. Results from a validation test suggest its COVID-19 test is 100% accurate: In the study, it didn't miss any positives, and it didn't report any false positives either.

In India, CoSara will manufacture test kits the joint venture will sell there. Co-Diagnostics' partner expects to begin filling orders immediately following the successful evaluation of those test kits by Indian regulators.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$3.18 (1.60%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.